NetworkNewsWire Editorial Coverage:
For the growing population of investors within the cannabis market,
marijuana-related portfolios are frequently designed to be diverse
— an advisable investment strategy for any trading portfolio. From
the cultivation side of the cannabis sector to
biotech/medical/pharmaceutical, ancillary services, cannabis oils,
edibles and beyond, the different avenues for marijuana investment
are abundant. For companies like Earth Science Tech, Inc.
(ETST) (ETST
Profile), the existence of diversity within its own
operations offers a similar advantage, enabling the company to
touch on and benefit from the success of various subsectors within
the cannabis market. Though uniquely structured, ETST is paced
alongside other cannabis industry players like Insys
Therapeutics, Inc. (INSY), Namaste Technologies,
Inc. (CSE: N) (OTCMKTS: NXTTF), Corbus
Pharmaceuticals Holdings, Inc. (CRBP) and Emerald
Health Therapeutics, Inc. (TSX.V: EMH) (OTCQX: EMHTF).
A Diverse Arena
The forward-march of cannabis legalization throughout North
America has led to record-breaking growth within this market, and
business opportunities have gone far beyond the bud to include
assorted products like gourmet marijuana edibles, cannabis-derived
oils, cannabis-based pharmaceuticals, health and beauty products,
vape pens and smoking accessories, agricultural innovations,
payment solutions, and more.
As decriminalization efforts continue worldwide, the cannabis
market only grows stronger. A recent Bloomberg report cites
Brightfield Group’s prediction that legal cannabis sales will reach
$31 billion on a global level by 2021 (http://nnw.fm/Xo0Ts). Like the individual strands in a
rope, the diverse subsectors within the cannabis market are twining
together to form an increasingly strong whole.
Strength in Variety
For companies like Earth
Science Tech, Inc. (OTC: ETST), operating diversified
subsidiaries is proving to be favorable path of growth within the
cannabis market. The innovative biotech currently has three wholly
owned subsidiaries under its umbrella, building an effective tripod
of strength for the company. Though these subsidiaries are diverse
in nature, their synergy lies in the application of science to the
pursuit of optimal health.
Launched in February 2017, the Cannabis Therapeutics, Inc.
(“CTI”) subsidiary is purposed to develop proprietary
cannabinoid-based nutraceuticals and pharmaceutical products. At
the core of this mission are Earth Science Tech’s existing cannabis
cannabidiol (CBD) patent, IP and future technologies to be
developed.
Focused on exploring and harnessing the medicinal power of CBD,
CTI’s research and development efforts are geared toward the
development of CBD-based drugs and nutraceuticals; and the
integration of the CBD molecule with existing generic drug
molecules to make drugs more efficient with fewer and less severe
side effects.
The subsidiary’s pipeline includes two cannabinoid-based
pharmaceutical drugs and three cannabinoid-based nutraceutical
products for a variety of ailments, such as anxiety, depression,
triple negative breast cancer and fatty liver disease.
CTI positions ETST in the rapidly evolving cannabinoid-based
pharmaceuticals market, which Statista projects could reach $50
billion by the year 2029. Meanwhile, a report in Hemp Business
Journal predicts the CBD consumer market will grow to $2.1 billion
by 2020, while other industry experts expect an increase to almost
$3 billion by 2021.
Discovering New Revenue Streams
ETST again extended its reach in June 2017 when it entered into
a joint venture to launch its wholly owned KannBidoid, Inc. (“KBD”)
subsidiary (http://nnw.fm/c6VBH).
Positioned to take advantage of the recreational vape/smoke shop
space, each of KBD’s products is formulated with CBD and kanna — a
small groundcover plant natively found in southern Africa — sold
and distributed in the form of edibles and vapes/e-liquids
products.
Rooted Research & Development
Though not centered on cannabis, ETST’s Earth Science
Pharmaceutical, Inc. subsidiary represents the core of the
company’s R&D capabilities.
Earth Science Pharmaceutical is focused on the development of
low-cost, noninvasive diagnostic tools, medical devices, testing
processes, and vaccines for sexually transmitted infections (STI)
and/or diseases. Its first medical device, MSN-2, is a home
detection STI kit being prepared for molecular diagnostics
trials.
The subsidiary is managed by an executive team with years of
scientific, medical and business experience in health, research and
manufacturing. The expertise of this team — headed by ETST CEO and
SCO Dr. Michael Aubé and COO Nickolas Tabraue — provides each of
ETST’s subsidiaries a multi-dimensional approach to their
respective markets.
Strategic Expansion via Acquisition &
Partnerships
In 2017 Earth Science Tech also increased operational diversity
with the acquisition of Montreal-based Canna Inno Laboratories,
which provides ETST access to government grants for up to half of
its R&D expenditures.
ETST also has agreements with the Centre de Développement
Bioalimentaire du Québec (“CDBQ”), which specializes in helping
companies develop the processes needed to take a prototype
agro-food or nutraceutical product to industrial-scale production
for the marketplace; and with Brazilian company, Bionatus. Inc. to
develop a treatment for asthma (http://nnw.fm/PE43r).
Branded Cannabidiol
Leveraging the strategies of its subsidiaries, ETST continues to
raise brand visibility, offering full-spectrum, high-purity
hemp-derived CBD oil. In collaboration with the University of
Central Oklahoma and the DV Biologics Laboratory, the company is
conducting R&D projects designed to scientifically support the
health care benefits of its completely natural and organic CBD
oil.
Earth Science Tech’s products include CBD in the form of
vitamins, minerals, herbs, botanicals, personal care products,
homeopathics, functional foods and other products delivered in such
forms as capsules, tablets, soft gels, chewables, liquids, creams,
sprays, powders and whole herbs. They are available at retail
stores throughout the United States, as well as online.
The company has also started pre-launch human trials on a new
CBD formula to fight against the U.S. opioid epidemic. The new
formula, expected to decrease cravings and the negative effects of
withdrawal in addicts, is based on industrial hemp CBD oil mixed
with a known natural ingredient proven to help increase dopamine
levels.
2017 Performance Points to 2018 Potential
As discussed in a recent article (http://nnw.fm/pd0Md) and year-end review (http://nnw.fm/38VbO), ETST nearly doubled its revenues
in 2017 compared with the previous year, and a price target of more
than $4 has been set for its stock.
ETST’s achievements in 2017 add weight to Dr. Aubé’s positive
forecast for the company’s future.
“This past year has been amazing. I am elated about the start of
the New Year given all that we accomplished in 2017. … We have
built the foundation and infrastructure the Company needs to
succeed long-term … and I feel that we are now on the way to
becoming the next billion-dollar (in-capitalization) company on the
OTC Markets.”
Comparable Cannabis Players
Insys Therapeutics (INSY) is focused on
improving patient care by addressing unmet medical needs through
cannabinoids and novel drug delivery systems. The company’s
approved products include SYNDROS, a cannabinoid medicine used to
treat anorexia in adults with AIDS and to address nausea and
vomiting caused by chemotherapy, and SUBSYS, which is used to
manage breakthrough pain in adult cancer patients who have become
tolerant to opioid therapy.
Namaste Technologies (NXTTF) is an online
retailer of medical cannabis delivery systems, distributing
vaporizers and smoking accessories worldwide through e-commerce
websites in 26 countries and five distribution hubs. Through its
2017 acquisition of CannMart Inc., Namaste is pursuing a new
revenue vertical in online medical cannabis retail sales in the
Canadian market, with an aim of positioning itself as a retail
medical cannabis distribution leader in Canada. During 2018,
Namaste intends to establish a secure telemedicine portal that will
connect doctors with medical marijuana patients, allowing Canadian
patients to receive product recommendations via email and to have
their prescriptions filled via postal mail. The company further
plans to expand its product offerings in 2017 and to launch a
Canadian warehouse in the CannMart facility.
Corbus Pharmaceuticals Holdings (CRBP) is a
clinical-stage pharmaceutical company that is focused on developing
and commercializing novel therapeutics to treat rare, chronic and
serious inflammatory and fibrotic diseases. Lenabasum is the
company’s lead product candidate and is a novel synthetic oral
endocannabinoid-mimetic drug designed to resolve chronic
inflammation and fibrotic processes. It is currently being
evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis
and systemic lupus erythematosus.
Emerald Health Therapeutics (EMHTF) is an
emerging global cannabis player and, through its wholly owned
subsidiary Emerald Health Botanicals Inc., is a licensed producer
of medical marijuana in Canada through the Access to Cannabis for
Medical Purposes Regulations (ACMPR). The company currently
operates an indoor facility in Victoria, B.C., and is in the
process of constructing a 500,000-square-foot greenhouse in Metro
Vancouver that has expansion potential to 1 million square feet.
Emerald additionally owns 50 percent of Pure Sunfarms Inc. (a
partnership with Village Farms International Inc.), which is
currently converting just under half of its 1.1 million-square-foot
greenhouse in Delta, B.C., from a tomato-growing operation into a
cannabis-cultivation facility.
Broadening the Landscape
Diversity is advisable for any investment portfolio, and
innovative companies like Earth Science Tech are proving
diversity’s effectiveness as a business strategy as well. As the
global cannabis market continues to gain strength, the
above-mentioned companies are positioned to lead the way into the
foreseeable green future.
For additional information about Earth Science Tech, visit
Earth Science
Tech, Inc. (OTC: ETST).
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
NetworkNewsBreaks that summarize corporate news and
information, (3) enhanced press release services, (4) social media
distribution and optimization services, and (5) a full array of
corporate communication solutions. As a multifaceted financial news
and content distribution company with an extensive team of
contributing journalists and writers, NNW is uniquely positioned to
best serve private and public companies that desire to reach a wide
audience of investors, consumers, journalists and the general
public. NNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting
through the overload of information in today’s market, NNW brings
its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW are a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertake no
obligation to update such statements.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Emerald Health Therapeut... (QB) (USOTC:EMHTF)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Emerald Health Therapeut... (QB) (USOTC:EMHTF)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024
